 Hepacivirus
"Hepacivirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
| Descriptor ID |
D016174
|
| MeSH Number(s) |
B04.450.410 B04.820.250.475 B04.909.777.310.475
|
| Concept/Terms |
Hepacivirus- Hepacivirus
- Hepaciviruses
- Hepatitis C-Like Viruses
- Hepatitis C Like Viruses
- Hepatitis C-Like Virus
|
Below are MeSH descriptors whose meaning is more general than "Hepacivirus".
Below are MeSH descriptors whose meaning is more specific than "Hepacivirus".
This graph shows the total number of publications written about "Hepacivirus" by people in UAMS Profiles by year, and whether "Hepacivirus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2021 | 0 | 4 | 4 | | 2020 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2018 | 2 | 3 | 5 | | 2017 | 2 | 2 | 4 | | 2016 | 1 | 4 | 5 | | 2015 | 1 | 3 | 4 | | 2014 | 4 | 1 | 5 | | 2013 | 6 | 3 | 9 | | 2012 | 4 | 2 | 6 | | 2011 | 4 | 1 | 5 | | 2010 | 4 | 1 | 5 | | 2008 | 5 | 1 | 6 | | 2007 | 2 | 0 | 2 | | 2006 | 3 | 2 | 5 | | 2005 | 5 | 2 | 7 | | 2004 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 2 | 3 | | 2001 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hepacivirus" by people in Profiles over the past ten years.
-
Steinbrink JM, Miller C, Myers RA, Sanoff S, Mazur A, Burke TW, Byrns J, Jackson AM, Luo X, McClain MT. Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-na?ve recipients of HCV-infected donor kidneys. PLoS One. 2023; 18(1):e0280602.
-
Mazouz S, Salinas E, B?dard N, Filali A, Khedr O, Swadling L, Abdel-Hakeem MS, Siddique A, Barnes E, Bruneau J, Grakoui A, Shoukry NH. Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects. PLoS Pathog. 2022 11; 18(11):e1010968.
-
Belachew B, Gao J, Byrd AK, Raney KD. Hepatitis C virus nonstructural protein NS3 unfolds viral G-quadruplex RNA structures. J Biol Chem. 2022 11; 298(11):102486.
-
Abdelaziz H, Omar H, Khalil M, Cordie A, Mohamed R, AbdAllah M, Abdel Maksoud MH, El Garhy N, Ali L, El Serafy M, Esmat G, Doss W. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Rev Anti Infect Ther. 2022 05; 20(5):789-795.
-
Marecki JC, Belachew B, Gao J, Raney KD. RNA helicases required for viral propagation in humans. Enzymes. 2021; 50:335-367.
-
Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. J Infect Dis. 2021 10 28; 224(8):1410-1421.
-
Pro G, Tompkins DA, Azari S, Zaller N. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status. Drug Alcohol Depend. 2021 11 01; 228:109092.
-
Stuart JD, Salinas E, Grakoui A. Immune system control of hepatitis C virus infection. Curr Opin Virol. 2021 02; 46:36-44.
-
Rochlani Y, Diab K, Jorde UP. Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities. Curr Heart Fail Rep. 2020 08; 17(4):106-115.
-
Wassenaar TM, Jun SR, Robeson M, Ussery DW. Comparative genomics of hepatitis A virus, hepatitis C virus, and hepatitis E virus provides insights into the evolutionary history of Hepatovirus species. Microbiologyopen. 2020 02; 9(2):e973.
-
Zaller N, Ostrach B. HCV, injection drug use, and the importance of harm reduction in Kenya. Lancet Infect Dis. 2019 11; 19(11):1158-1159.
-
Marecki JC, Aarattuthodiyil S, Byrd AK, Penthala NR, Crooks PA, Raney KD. N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3. Bioorg Med Chem Lett. 2019 02 01; 29(3):430-434.
-
Zhang H, He Z, He X, Guo Y, Nelson DR, Modave F, Wu Y, Hogan W, Prosperi M, Bian J. Computable Eligibility Criteria through Ontology-driven Data Access: A Case Study of Hepatitis C Virus Trials. AMIA Annu Symp Proc. 2018; 2018:1601-1610.
-
Zaller N, Brinkley-Rubinstein L. Incarceration, drug use, and infectious diseases: a syndemic still not addressed. Lancet Infect Dis. 2018 12; 18(12):1301-1302.
-
Bisseye C, Mombo LE, Bie SMM, Edou A, Eko-Mba JM, Etho-Mengue JC, Mbacky K, Mongo-Delis A, M'batchi B, Nagalo BM. Trends of blood-borne infectious diseases in a rural blood donation center of southeast Gabon (Koula-Moutou). Pan Afr Med J. 2018; 31:81.
-
Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech MR, Safdar K, Blackard JT, Apewokin S, Paterno F, Sherman KE, Zucker SD, Anwar N, Shah SA. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018 05; 67(5):1673-1682.
-
Kanwal F, Pyne JM, Tavakoli-Tabasi S, Nicholson S, Dieckgraefe B, Storay E, Goetz MB, Kramer JR, Smith D, Sansgiry S, Tansel A, Gifford AL, Asch SM. A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. Health Serv Res. 2018 08; 53(4):2547-2566.
-
Maan R, Feld JJ, Duarte-Rojo A. Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply. Aliment Pharmacol Ther. 2017 08; 46(3):379-380.
-
Thandassery RB, Kaabi SA, Soofi ME, Tharian B, Singh R. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatol Int. 2017 Jul; 11(4):401-408.
-
Ferucci ED, Choromanski TL, Varney DT, Ryan HS, Townshend-Bulson LJ, McMahon BJ, Wener MH. Prevalence and correlates of hepatitis C virus-associated inflammatory arthritis in a population-based cohort. Semin Arthritis Rheum. 2017 12; 47(3):445-450.
-
Jarret A, McFarland AP, Horner SM, Kell A, Schwerk J, Hong M, Badil S, Joslyn RC, Baker DP, Carrington M, Hagedorn CH, Gale M, Savan R. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med. 2016 12; 22(12):1475-1481.
-
Hong M, Schwerk J, Lim C, Kell A, Jarret A, Pangallo J, Loo YM, Liu S, Hagedorn CH, Gale M, Savan R. Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med. 2016 11 14; 213(12):2539-2552.
-
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016 11; 44(10):1090-1101.
-
Larney S, Zaller ND, Dumont DM, Willcock A, Degenhardt L. A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations. Ann Epidemiol. 2016 08; 26(8):570-578.e2.
-
Thandassery RB, Al Kaabi S, Soofi ME, Mohiuddin SA, John AK, Al Mohannadi M, Al Ejji K, Yakoob R, Derbala MF, Wani H, Sharma M, Al Dweik N, Butt MT, Kamel YM, Sultan K, Pasic F, Singh R. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C? J Clin Gastroenterol. 2016 07; 50(6):518-23.
-
Liu S, Chen R, Hagedorn CH. Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells. PLoS One. 2015; 10(7):e0131358.
-
Pothineni NV, Rochlani Y, Vallurupalli S, Kovelamudi S, Ahmed Z, Hakeem A, Mehta JL. Comparison of Angiographic Burden of Coronary Artery Disease in Patients With Versus Without Hepatitis C Infection. Am J Cardiol. 2015 Oct 01; 116(7):1041-4.
-
Reynolds KA, Cameron CE, Raney KD. Melting of Duplex DNA in the Absence of ATP by the NS3 Helicase Domain through Specific Interaction with a Single-Strand/Double-Strand Junction. Biochemistry. 2015 Jul 14; 54(27):4248-58.
-
Meyer K, Kwon YC, Liu S, Hagedorn CH, Ray RB, Ray R. Interferon-a inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep. 2015 Mar 11; 5:9012.
-
Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JL. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol. 2014 Dec 15; 114(12):1841-5.
-
Choi SS, Claridge LC, Jhaveri R, Swiderska-Syn M, Clark P, Suzuki A, Pereira TA, Mi Z, Kuo PC, Guy CD, Pereira FE, Diehl AM, Patel K, Syn WK. Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clin Sci (Lond). 2014 Jun; 126(12):845-55.
-
Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health. 2014 Jun; 104(6):e69-74.
-
Deneke MG, Dranoff JA, Duarte-Rojo A. [Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy]. Rev Gastroenterol Mex. 2014 Jan-Mar; 79(1):64-6.
-
Zeba MT, Sanou M, Bisseye C, Kiba A, Nagalo BM, Djigma FW, Compaor? TR, Nebi? YK, Kienou K, Sagna T, Pietra V, Moret R, Simpor? J. Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso. Blood Transfus. 2014 Jan; 12 Suppl 1:s54-7.
-
Ali N, Allam H, Bader T, May R, Basalingappa KM, Berry WL, Chandrakesan P, Qu D, Weygant N, Bronze MS, Umar S, Janknecht R, Sureban SM, Huycke M, Houchen CW. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One. 2013; 8(11):e80304.
-
McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M, Savan R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014 Jan; 15(1):72-9.
-
Liu S, Chen R, Hagedorn CH. Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures. J Gen Virol. 2014 Feb; 95(Pt 2):423-433.
-
Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA, Dash S. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol. 2014 Jan; 184(1):214-29.
-
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat. 2014 Aug; 21(8):568-77.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|